ArticleOpen forum infectious diseases2020
The Course of Mild and Moderate COVID-19 Infections-The Unexpected Long-Lasting Challenge.
Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 37 citations in OpenAlex.
- Seven Months after Mild COVID-19: A Single-Centre Controlled Follow-Up Study in the District of Constance (FSC19-KN).International journal of clinical practice · 2022Trial
- Trial
- Studying COVID-19 transmission in US state prisons using an agent-based modelling approach: a simulation study.BMJ open · 2025Article
- The Safety of Nebulized Conjugated Linoleic Acid for COVID-19 Respiratory Tract Infections.Cureus · 2025Article
- Longitudinal analysis of Covid-19 infection trends and in-hospital mortality across six pandemic waves in Tunisia.Archives of public health = Archives belges de sante publique · 2025Article
- Medical events in SARS-Cov-2 infected psychiatric inpatients with and without pre-existing co-morbid medical conditions.Heliyon · 2023Article
- Prevalence of oral complications in the course of severe SARS-CoV-2 infection under mechanical non-invasive ventilation.European journal of medical research · 2023Article
- Lung perfusion assessed by SPECT/CT after a minimum of three months anticoagulation therapy in patients with SARS-CoV-2-associated acute pulmonary embolism: a retrospective observational study.Respiratory research · 2022Observational
- COVID-19 and athletes: Endurance sport and activity resilience study-CAESAR study.Frontiers in physiology · 2022Article
- COVID-19, what could sepsis, severe acute pancreatitis, gender differences, and aging teach us?Cytokine · 2021Review
- Status evaluation of provinces affected by COVID-19: A qualitative assessment using fuzzy system.Applied soft computing · 2021Article
- Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients.Scientific reports · 2021Article
- Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy?Regenerative medicine · 2021Review
- Pulmonary Pathology of COVID-19 Following 8 Weeks to 4 Months of Severe Disease: A Report of Three Cases, Including One With Bilateral Lung Transplantation.American journal of clinical pathology · 2021Article
- Impact of Lockdown Measures and Meteorological Parameters on the COVID-19 Incidence and Mortality Rate in Bangladesh.Infectious microbes & diseases · 2021Article
- Acute Symptoms of Mild to Moderate COVID-19 Are Highly Heterogeneous Across Individuals and Over Time.Open forum infectious diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe course of disease in mild and moderate COVID-19 has many implications for mobile patients, such as the risk of spread of the infection, precautions taken, and investigations targeted at preventing transmission.
methodsThree hundred thirty-one adults were hospitalized from January 21 to February 22, 2020, and classified as severe (10%) or critical (4.8%) cases; 1.5% died. Two hundred eighty-two (85.2%) mild or moderate cases were admitted to regular wards. Epidemiological, demographic, clinical, chest computed tomography (CT) scan, laboratory, treatment, and outcome data from patient records were analyzed retrospectively.
resultsPatients were symptomatic for 9.82±5.75 (1-37) days. Pulmonary involvement was demonstrated on a chest CT scan in 97.9% of cases. It took 16.81±8.54 (3-49) days from the appearance of the first symptom until 274 patients tested virus-negative in naso- and oropharyngeal (NP) swabs, blood, urine, and stool, and 234 (83%) patients were asymptomatic for 9.09±7.82 (1-44) days. Subsequently, 131 patients were discharged. One hundred sixty-nine remained in the hospital; these patients tested virus-free and were clinically asymptomatic because of widespread persisting or increasing pulmonary infiltrates. Hospitalization took 16.24±7.57 (2-47) days; the time interval from the first symptom to discharge was 21.37±7.85 (3-52) days.
conclusionsWith an asymptomatic phase, disease courses are unexpectedly long until the stage of virus negativity. NP swabs are not reliable in the later stages of COVID-19. Pneumonia outlasts virus-positive tests if sputum is not acquired. Imminent pulmonary fibrosis in high-risk groups demands follow-up examinations. Investigation of promising antiviral agents should heed the specific needs of mild and moderate COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.